NASDAQ$PODD

Insulet Corp. · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Insulet's Q3 2023 financial results were announced, featuring a 27% year-over-year revenue increase and raised full-year revenue guidance.

Insulet Corporation reported a strong third quarter with a 27% increase in revenue compared to the previous year, driven by high demand for Omnipod 5. The company raised its full-year revenue guidance to a range of 26% to 27%.

  • Third quarter revenue reached $432.7 million, a 27.0% increase year-over-year.
  • Total Omnipod revenue increased by 29.4% to $422.0 million.
  • Gross margin improved to 67.8%, up 1,250 basis points compared to the prior year.
  • Operating income was $54.8 million, representing 12.7% of revenue, up 1,180 basis points year-over-year.

Headline financials

Total Revenue

$433M

Previous: $341M+27.0%
EPS (adj)

$0.71

Previous: $0.45+57.8%
Gross Margin

67.8%

Previous: 55.3%+22.6%
Adjusted EBITDA

$82.8M

Previous: $62.8M+31.8%
Capital Expenditures

-$46.3M

Previous: -$58.5M+20.9%
Free Cash Flow

$5.6M

Previous: -$63.7M+108.8%
Net Income

$51.9M

Previous: -$5.2M+1098.1%
Operating Income

$54.8M

Previous: $2.9M+1789.7%
Gross Profit

$293M

Previous: $188M+55.8%
Cash & Equivalents

$685M

Previous: $722M-5.1%
Total Assets

$2.47B

Previous: $2.17B+13.9%
R&D Expense

$57.8M

No prior period
Stock-Based Comp

$10.5M

Previous: $9M+16.7%

Revenue & EPS history

Insulet · Revenue · Quarterly

$433M

Q3 2023+27%vs Q3 2022
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Revenue by segment

Insulet · $433M total across 3 segments · Q3 2023

  • U.S. Omnipod
    $321M+34.6%
  • International Omnipod
    $101M+15.2%
  • Drug Delivery
    $10.7M-27.2%

Forward guidance

Insulet expects revenue growth of 22% to 25% for the quarter ending December 31, 2023.

Tailwinds

  • Total Omnipod revenue is projected to grow by 22% to 25%.
  • U.S. Omnipod revenue is expected to increase by 28% to 31%.
  • International Omnipod revenue is anticipated to rise by 5% to 8%.
  • Drug Delivery revenue is forecasted to be between $3 million and $5 million (0% to 70% growth).
  • Company is raising its expected gross margin to the mid-point of the range of 66% to 67%

Headwinds

  • There are no specific negative points mentioned in the provided guidance summary.
  • The guidance is based on current expectations and is subject to various risks and uncertainties.
  • Future results may differ materially from the provided guidance.
  • The company does not undertake to update any forward-looking statement.
  • The company now expects operating margin in the range of 9% to 10%, closer to the high-end of the range

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+3.0%

Avg return

Earnings day

+4.0%

Avg return

5 days after

+5.2%

Avg return

30 days after

65%

41 / 63 earnings

Positive

+20.7%

Q1 2025

Best reaction

-16.8%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.1%+3.8%+1.4%
Q4 2025+3.5%+1.2%-7.8%
Q3 2025+2.8%+3.8%-3.2%
Q1 2025+20.7%+25.1%+21.3%
Q4 2024-1.9%-6.1%-6.9%
Q3 2024+12.0%+15.0%+10.9%
Q2 2024-4.3%+2.2%+12.8%
Q1 2024-5.5%-1.9%+9.0%
Q4 2023-4.3%-13.4%-14.6%
Q3 2023+18.1%+17.5%+39.6%
Q2 2023-11.9%-13.6%-31.6%
Q1 2023+2.4%-0.4%-12.4%
Q4 2022+2.3%-4.0%+7.8%
Q3 2022+19.6%+16.3%+17.7%
Q2 2022+2.4%-0.8%-2.5%
Q1 2022-16.8%-23.0%-13.9%
Q4 2021+8.9%+12.9%+7.4%
Q3 2021-1.3%+2.0%-15.6%
Q2 2021-1.3%+0.1%+8.4%
Q1 2021-11.4%-13.0%+2.8%
Q4 2020+2.3%+1.0%+1.0%
Q3 2020+14.6%+14.4%+16.0%
Q2 2020+1.1%-7.7%-4.9%
Q1 2020+5.4%+6.8%-13.3%
Q4 2019-13.2%-8.4%-14.2%
Q3 2019+9.9%+16.4%+26.5%
Q2 2019+18.4%+26.0%+30.0%
Q1 2019+14.0%+20.9%+29.4%
Q4 2018+5.1%+7.7%+6.6%
Q3 2018+0.4%-2.4%-4.9%
Q2 2018+2.4%+2.6%+24.3%
Q1 2018-3.6%-4.3%+9.0%
Q4 2017+3.6%-1.1%+8.6%
Q3 2017+18.9%+22.7%+21.0%
Q2 2017+6.5%+8.6%+15.5%
Q1 2017-5.8%-4.6%+0.9%
Q4 2016-5.2%+0.7%-7.2%
Q3 2016+9.9%+10.3%+3.9%
Q2 2016+18.5%+23.3%+22.2%
Q1 2016-4.0%
Q4 2015+9.0%
Q3 2015+13.2%
Q2 2015+10.0%
Q1 2015-11.0%
Q4 2014-4.5%
Q3 2014+5.1%
Q2 2014-2.2%
Q1 2014-14.0%
Q3 2013-3.4%
Q2 2013+10.2%
Q1 2013+12.0%
Q4 2012+9.3%
Q3 2012+4.2%
Q2 2012+4.8%
Q1 2012+2.1%
Q4 2011-3.5%
Q3 2011+0.5%
Q2 2011+2.9%
Q1 2011+0.6%
Q4 2010-2.0%
Q3 2010+2.5%
Q2 2010+0.3%
Q1 2010+11.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro